Traditional drug development operates against static target product profiles across siloed preclinical and clinical departments. George envisions dynamic, AI-connected profiles that update continuously as new internal molecular data, global competition, and clinical findings emerge.
Platforms built purely on technical skill often struggle to create commercially viable medicines. George recommends placing experienced drug developers, such as CMOs, at the core and wrapping proprietary and off-the-shelf computational capabilities around them to solve specific unmet medical needs.
Early clinical trials offer the highest return on AI investment because they involve fewer patients, lower costs, and shorter timelines. Applying models here enables developers to enrich patient selection and forecast late-phase outcomes before committing massive capital to phase three studies.
The traditional model of cheaply in-licensing early-stage molecules from China for development in the West is disappearing as valuation gaps close. Investors and biopharma companies must pivot toward collaborative joint ventures that grant local Chinese innovators pipeline equity.
Biotech developers are migrating toward transnational development models that execute early clinical de-risking in regions like China, Australia, or the UK. This approach accelerates progression while maintaining strict data quality standards required by Western regulators for commercial approval.
George argues that the primary vulnerability in the American biotech landscape is not a lack of venture capital, but potential reductions in basic NIH research grants. Sustaining fundamental scientific discovery and cutting regulatory friction matter more than state-backed investment vehicles.
Venture investors are reluctant to back open-ended platform technologies without immediate clinical applications. Even cutting-edge modalities such as cell engineering must define specific therapeutic indications and clear target product profiles from day one.